New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
35th Annual Aerospace/Defense Conference is being held in New York on February 5-6 with webcasted company presentations to begin on February 5 at 9 am. Webcast Link
News For A;CVU;EGL;ANTH;CRS;KEYW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.
12:36 EDTANTHAnthera begins SOLUTION clinical study of CF treatment
Anthera Pharmaceuticals announced the initiation of the SOLUTION Phase 3 clinical study evaluating the efficacy and safety of Sollpura, a microbial derived, biotech pancreatic enzyme replacement therapy, compared to an approved, porcine-derived, enteric-coated product for the treatment of exocrine pancreatic insufficiency. The Phase 3 SOLUTION clinical study is a multicenter, randomized, open-label, assessor-blind, non-inferiority, active-comparator study designed to evaluate the efficacy and safety of Sollpura in people with EPI due to cystic fibrosis. This pivotal study is intended to evaluate the non-inferiority of Sollpura compared with a commercially available PERT in a population enriched for PERT responders. The primary efficacy endpoint of this study will be comparative efficacy measured as the change in the coefficient of fat absorption at the end of therapy. Results from the SOLUTION clinical study are anticipated to support marketing approval for Sollpura as a treatment for exocrine pancreatic insufficiency.
October 1, 2015
16:21 EDTKEYWKEYW's Hawkeye G selected by U.S. energy company for threat detection
KEYW 's wholly-owned subsidiary Hexis Cyber Solutions announced that one of the nation's leading energy providers has selected HawkEye G for next generation threat detection and response. This represents the first seven-figure deal for the recently released HawkEye G 3.0.
September 29, 2015
05:24 EDTKEYWHexis Cyber Solutions enters into partnership with Exclusive Networks
Subscribe for More Information
September 25, 2015
09:03 EDTKEYWKEYW wins second contract option exercise for airborne collection services
Subscribe for More Information
September 24, 2015
17:04 EDTAMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information
10:41 EDTKEYWKEYW announces first product sale of KeyRadar
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use